Childhood polycythemia vera and essential thrombocythemia: Does their pathogenesis overlap with that of adult patients?

Haematologica

Volumn 93, Issue 2, 2008, Pages 169-172

  Teofili, Luciana ^a   Foà, Robin ^b   Giona, Fiorina ^b   Larocca, Luigi Maria ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; JANUS KINASE 2; THROMBOPOIETIN;

CHILDHOOD DISEASE; FAMILY HISTORY; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; MOLECULAR CLONING; MORBIDITY; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; POLYCYTHEMIA VERA; PREVALENCE; REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

ADOLESCENT; ADULT; AGE FACTORS; ALGORITHMS; AMINO ACID SUBSTITUTION; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; ISOANTIGENS; JANUS KINASE 2; MALE; MEMBRANE GLYCOPROTEINS; MUTATION, MISSENSE; POLYCYTHEMIA VERA; RECEPTORS, CELL SURFACE; RECEPTORS, THROMBOPOIETIN; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 40849147397     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12002     Document Type: Review

References (39)

1. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997;15: 173-89.
2. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-9.
3. Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000;110:751.
4. Marlow AA, Fairbanks VF. Polycythemia vera in an eleven-year-old girl. N Engl J Med 1960;263:950-2.
5. Danish EH, Rasch CA, Harris JW. Polycythemia vera in childhood: case report and review of the literature. Am J Hematol 1980;9:421-8.
6. Chistolini A, Mazzucconi MG, Ferrari A, la Verde G, Ferrazza G, Dragoni F, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990;75:537-40.
7. Perea G, Remacha A, Besses C, Jimenez M, Florensa L, Cervantes F. Is polycythemia vera a serious disease in young adults? Haematologica 2001;86:543-4.
8. Turker M, Ozer EA, Oniz H, Atabay B, Yaprak I. Polycythemia vera in a 12-year-old girl: a case report. Pediatr Hematol Oncol 2002;19:263-6.
9. Randi ML, Putti MC, Fabris F, Sainati L, Zanesco L, Girolami A. Features of essential thrombocythaemia in childhood: a study of five children. Br J Haematol 2000;108:86-9.
10. Florensa L, Zamora L, Besses C, Ortega JJ, Bastida P, Toll T, et al. Cultures of myeloid progenitor cells in pediatric essential thrombocythemia. Leukemia 2002;16:1876-7.
11. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997;23:339-47.
12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
13. Cario H. Childhood polycythemias/ erythrocytoses: classification, diagnosis, clinical presentation, and treatment. Ann Hematol 2005;84:137-45.
14. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005;129:165-77.
15. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997;90:2057-61.
16. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998; 18:49-52.
17. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol 1999;107:310-16.
18. Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi, et al. Familial essential thrombocythemia associated with one-base deletion in the 5′-untranslated region of the thrombopoietin gene. Blood 1998;92:1091-96.
19. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood 1999;94:1480-2.
20. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103: 4198-200.
21. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280:22788-92.
22. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365: 1054-61.
23. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434: 1144-8.
24. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
25. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
26. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.
27. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41[Suppl 3]:1-5.
28. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108:346-52.
29. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006;107: 2206-11.
30. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005;130:800-1.
31. Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood 2006;107:4572-3.
32. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003;102:3793-6.
33. Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol 2005;42:266-73.
34. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007; 25:1048-52.
35. Randi ML, Putti MC, Scapin M, Pacquola E, Tucci F, Micalizzi C, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006;108:3600-2.
36. El-Moneim AA, Kratz CP, Boll S, Rister M, Pahl HL, Niemeyer CM. Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. Pediatr Blood Cancer 2007;49:52-5.
37. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.
38. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
39. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007;110:3384-6.